Motley Fool  11 hrs ago  Comment 
Up to seven Big Pharma and biotech blue-chip companies could make a bid for Medivation.
New York Times  May 25  Comment 
The French drug maker said it was seeking the consent of the American company’s shareholders to replace directors with a slate of its own candidates.
Clusterstock  May 13  Comment 
By Greg Roumeliotis and Lauren Hirsch (Reuters) - France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a...
FiercePharma  May 10  Comment 
Medivation opens books to Pfizer, Amgen as bidders circle: Reuters tracystaton Tue, 05/10/2016 - 09:19
Benzinga  May 10  Comment 
Medivation Inc (NASDAQ: MDVN) had an offer on the table to be acquired by Sanofi SA (ADR) (NYSE: SNY) for $9.3 billion, or $52.50 per share. Medivation rejected Sanofi's buyout offer and argued that its own business plan and strategy will...
Clusterstock  May 9  Comment 
By Greg Roumeliotis and Pamela Barbaglia (Reuters) - U.S. cancer drug maker Medivation Inc has decided to explore a sale following a $9.3 billion acquisition offer from France's Sanofi SA and interest from other companies, people familiar with...
Clusterstock  May 8  Comment 
There's a new bidding war brewing in the drug industry. Last week, Sanofi went public with a $9.3 billion bid for Medivation, a San Francisco-based biotech that already has one drug on the market to treat prostate cancer. Medivation turned...
Benzinga  May 6  Comment 
Barclays has raised the price target on the shares of Medivation Inc (NASDAQ: MDVN) to $70 from $48, driven by the increased visibility on duration gains and pipeline front. The sum-of-the-parts valuation by analyst Geoff Meacham, who has an...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki